ArticleMolecular and cellular biology2021
Nuclear Lamin A/C Expression Is a Key Determinant of Paclitaxel Sensitivity.
Article in Molecular and cellular biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 38 citations in OpenAlex.
- Lamin subtype expression in Merkel-cell carcinoma: its relation to polyomavirus infection and tumor metastasis.Histochemistry and cell biology · 2026Article
- Paclitaxel in oncology: balancing anticancer efficacy with potential carcinogenic risks and resistance mechanisms.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Disruption of microtubules with low intensity ultrasound rescues hair follicle damage by paclitaxel in mouse models.Nature communications · 2026Article
- Paclitaxel compromises nuclear integrity in interphase through SUN2-mediated cytoskeletal coupling.Journal of cell science · 2026Article
- Red blood cell-derived extracellular vesicles enable cisplatin and cetuximab combined therapy against triple-negative breast cancer.Journal of nanobiotechnology · 2026Article
- Killing Glioblastoma Cells with Glycosylated Indolocarbazole-Based Derivative LCS1269: A Potential Crosstalk Between Micronuclei Formation and the Concurrent Induction of Apoptosis, Necroptosis, and Pyroptosis.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Micronuclei: origins, assays, mechanisms, diseases and treatments.Signal transduction and targeted therapy · 2026Review
- Variable A-type lamin expression in Merkel cell carcinoma cell lines and its association with nuclear integrity.Scientific reports · 2026Article
- The molecular mechanisms of pyroptosis and its implications in tumor immunotherapy.Molecular cancer · 2026Review
- Research trends and hotspots of Lamin family in cancer: a bibliometric analysis.Discover oncology · 2025Article
- The Persistent Power of the Taxane/Platin Chemotherapy.Cancers · 2025Review
- Radiation symptoms resemble laminopathies and the physical underlying cause may sit at the lamin A C-terminus.Molecular medicine (Cambridge, Mass.) · 2025Article
- Effects of cisplatin, paclitaxel combined with high-dose methotrexate as adjuvant therapy on survival rates in osteosarcoma patients, and analysis of influencing factors.American journal of cancer research · 2025Article
- The Second Selectivity of Taxanes to Malignant Cells --- Nuclear Envelope Malleability.Journal of Cancer · 2025Article
- Mechanosensitive nuclear uptake of chemotherapy.Science advances · 2024Article
- Cancer nuclear envelope rupture and repair in taxane resistance.Medical review (2021) · 2024Review
- Review
- Abrogating Metastatic Properties of Triple-Negative Breast Cancer Cells by EGFR and PI3K Dual Inhibitors.Cancers · 2023Article
- Article
- Cell death in cancer chemotherapy using taxanes.Frontiers in pharmacology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Paclitaxel is a key member of the Taxane (paclitaxel [originally named taxol], docetaxel/Taxotere) family of successful drugs used in the current treatment of several solid tumors, including ovarian cancer. The molecular target of paclitaxel has been identified as tubulin, and paclitaxel binding alters the dynamics and thus stabilizes microtubule bundles. Traditionally, the anticancer mechanism of paclitaxel has been thought to originate from its interfering with the role of microtubules in mitosis, resulting in mitotic arrest and subsequent apoptosis. However, recent evidence suggests that paclitaxel operates in cancer therapies via an as-yet-undefined mechanism rather than as a mitotic inhibitor. We found that paclitaxel caused a striking break up of nuclei (referred to as multimicronucleation) in malignant ovarian cancer cells but not in normal cells, and susceptibility to undergo nuclear fragmentation and cell death correlated with a reduction in nuclear lamina proteins, lamin A/C. Lamin A/C proteins are commonly lost, reduced, or heterogeneously expressed in ovarian cancer, accounting for the aberration of nuclear shape in malignant cells. Mouse ovarian epithelial cells isolated from lamin A/C-null mice were highly sensitive to paclitaxel and underwent nuclear breakage, compared to control wild-type cells. Forced overexpression of lamin A/C led to resistance to paclitaxel-induced nuclear breakage in cancer cells. Additionally, paclitaxel-induced multimicronucleation occurred independently of cell division that was achieved by either the withdrawal of serum or the addition of mitotic inhibitors. These results provide a new understanding for the mitotis-independent mechanism for paclitaxel killing of cancer cells, where paclitaxel induces nuclear breakage in malignant cancer cells that have a malleable nucleus but not in normal cells that have a stiffer nuclear envelope. As such, we identify that reduced nuclear lamin A/C protein levels correlate with nuclear shape deformation and are a key determinant of paclitaxel sensitivity of cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.